NaPro/Ivax Paxene
Executive Summary
Companies terminate paclitaxel development and marketing agreement. Ivax will return its 1.1 mil. shares of NaPro stock and pay $6 mil. in exchange for a royalty-free, non-exclusive license to NaPro's pending paclitaxel patents. Ivax will also make additional payments of up to $6.4 mil. upon issuance of a patent. NaPro will continue to supply Ivax with paclitaxel while Ivax finds a new supplier, and NaPro is seeking a new marketing partner. An NDA for Paxene use in Kaposi's sarcoma is blocked until 2004 by Bristol's orphan exclusivity for Taxol
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth